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Abstract:
Neurodegeneration is a pathological condition associated with a progressive loss of neurons, and
occurs in many neurological disorders including Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Lou Gehrig’s disease (ALS). It is the most common cause of dementia among people 65
and older. With the increasing of life expectancy, the prevalence of neurodegenerative diseases is
also increasing rapidly. However, the cause of this disorder is largely unknown, and no effective
drugs are available to treat the disease process. Therefore, it is crucial to identify new target(s) and
strategies for therapeutic interventions. Cytoskeletal defects followed by dysfunction is a major
characteristic of neurodegenerative diseases. During neurodegeneration microtubules (MTs) and
proteins associated with MTs are severely altered. Tau is a stabilizing MT-associated protein
(MAP) and in normal conditions, tau binds to MT, stabilizing neuron structure and integrity. In
Alzheimer’s disease (AD) and in other tauapathies, tau is hyper-phosphorylated leading to tau
aggregation and NFT (neurofibriliary tangles) formation, and this pathway emerged as a major
feature in the pathogenesis of AD and associated illness. Over activation of GSK3, a downstream
effector of PI3K pathway has been shown to play key roles in tau hyperphosphorylation. Previous
results from our laboratory have shown that G, an important component of GPCR pathway
promotes microtubule (MT) assembly and induces neuronal differentiation of PC12 cells and
blocking the interaction between G and tubulin/MTs using G-blocking peptide GRK-CT,
disrupted MTs, inhibited neurite outgrowth, and induced axonal damage indicating the possible
involvement of G in neurodegeneration. Although G has been implicated in familial AD, and
has been connected to APP (Amyloid precursor protein)-dependent toxicity, it has not been
investigated as potential pathway for inducing neurodegeneration. In the current investigation we
used human neuronal cells SHSY5Y to further understand the mechanism by which G is
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involved in neuronal differentiation and neurodegeneration. I hypothesize that G is involved in
neurodegeneration by disrupting MTs, altering phosphorylation of tau protein, and G-mediated
downstream PI3K/pAkt/pGSK3 signaling pathway. This hypothesis was tested in the current
study. Gallein, an inhibitor of G, and Tideglusib, a GSK3 inhibitor were used to elucidate the
proposed signaling pathway. SHSY5Y cells are a neuroblastoma derived cell line that is commonly
used in vitro to understand the process of neurodegeneration (ND) was included in the current
thesis.
In Specific Aim 1, using biochemical, and immunoconfocal methodologies, I have demonstrated
that Gallein (GAL) inhibited neurite formation and disrupted MT assembly. Surprisingly,the
immunoblot analysis using p396 TAU (ser at 396 position) specific antibody, I observed the
expression of phosphorylated tau was reduced in the presence of GAL, suggesting that MT
disruption could also be associated with inhibition of tau phosphorylation (hypo-) similar to that
observed in hyper-phosphorylation of Tau protein (Cortés-Gómez, M. Á., et al.,2020). In
Specific Aim-2, I have demonstrated the PI3K pathway was affected by GAL as phosphorylation
of Akt and GSK3 was inhibited. Similar to GAL, we found tideglusib also disrupted MTs and
neurite formation. As found with GAL, tideglusib decreased expression of pAKT, pGSK3, and
ps396 Tau in SHSY5Y cells. Tideglusib has been used earlier in phase 2 clinical trial for AD
patients. However, the primary outcome from the trial was negative. My results indicating that
tideglusib disrupt MTs and neurite formation, could account for this outcome. The current results
also suggest that that both G and its downstream effector GSK3 could work in concert to
disrupt MTs, inhibit neuronal differentiation, and induce neurodegeneration. The study also
indicates that more caution should be taken for developing drugs for the treatment of
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neurodegeneration, and should first be tested for their effectiveness in vitro cell culture system
for MT assembly/ neuronal differentiation.
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Introduction
1.1 Neurodegeneration
Neurodegeneration is characterized by the progressive loss of neurons and is seen in neurological
diseases such as, Alzheimer's disease (AD), Parkinson’s disease (PD), and other forms of
dementia. At present the mechanism and the cause associated with these neurodegenerative
disorders is unknown. There is no effective treatment to stop or slow down the disease process.
Moreover, although there are treatments that produce some symptomatic relief, many become
ineffective over time and can even produce disruptive symptoms of their own (Madireddy &
Madireddy, 2019). Thus, it is urgent to develop more effective treatments for neurodegenerative
disorders. A common characteristic for these disorders is disruption of the cytoskeleton and
aggregation of microtubule associated proteins (Dave R.H et al., 2009).
Alzheimer's disease (AD) is currently the most common neurodegenerative disease (ND).
The pathology of AD is characterized by two hallmarks, the presence of Amyloid beta plaques and
neurofibrillary tangles (NFT). In normal neurons Tau protein participates in microtubule (MT)
stabilization by binding to the MTs. In AD hyper- phosphorylated Tau is not able to bind to MT
forming aggregates. Tau aggregates are disposed in the cell forming neurofibrillary tangles.
Disruption of MT leads to axonal damage leading to an impairment in synaptic transmission.
(Šimić et al., 2016)
Parkinson's disease hallmarks include Lewy bodies composed of alpha-synuclein
aggregated proteins including tubulin, microtubule-associated protein 1 (MAP1), and MAP2.The
Substantia Nigra is the brain region most affected by PD. The Substantia Nigra is the region of the
brain where most dopaminergic neurons are found. PD predominately affects dopamine producing
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neurons. Loss of neurons in these region and cytoskeletal impairment are thought to lead to the
debilitating motor skill loss seen in PD. (Majounie et al., 2013)
1.2 Neuronal Cytoskeleton, Microtubule Dynamics and Neurodegeneration
Neurons are the brain cells responsible for receiving, processing, and transmitting
information. During neuronal differentiation two separate domains extend from the cell body:
multiple short projections called dendrites that serve to receive signals from adjacent neurons as
well as a long slender axon which transmits information. The cytoskeleton provides structural
organization of the neuron. It also serves as tracks for intracellular transport and comprises the
core framework of cellular morphologies. The ability to achieve proper connections between the
correct sets of cells, is fundamental for the proper functioning of the nervous system. This essential
function is dependent on the polarized organization of axons and dendrites (Roychowdhury &
Sierra-Fonseca, 2017). The main components of the cytoskeleton are MTs and actin filaments.
MTs form dense, parallel arrays in axons and dendrites that are required for the growth and
maintenance of neurites. In contrast, actin filaments are enriched in the growth cone and organized
into long bundles forming filamentous protrusions (filopodia) or veil-like sheets of branched actin
(lamellipodia). Microtubules are dynamic structures that undergo continual assembly and
disassembly within the cell. These core cytoskeleton components are assembled through head to
tail polymerization of alpha and beta tubulin heterodimers. Thus, resulting in two different
asymmetric polarized polymers ends, referred to as plus and minus ends. Due to their highly
dynamic structure Microtubules can rapidly go through cycles of assembly and disassembly.
During neurodegeneration, the proper association and arrangement of cytoskeleton components is
severely compromised. Several hallmark conditions, such as altered protein folding, amyloid
plaques, neurofibrillary tangles, Lewy bodies, impaired cellular transport, and increased oxidative
2

stress among many others are observed during neurodegeneration (Fig.1).

However, the

mechanism by which ND diseases are triggered and further progress is poorly understood.

Figure. 1 Healthy and Degenerated Neuronal Cytoskeleton. Representation of the
cytoskeletal organization in a healthy neuronal cell (upper panel). Microtubules form dense arrays
mainly along the axon and dendrites of the cell (shown in red). The actin filaments, represented in
green, localize primarily on the tips of the processes, forming lamellipodium, and fillipodium.
Lastly, shown in blue are the microtubule-associated proteins, which play a role in the dynamic
stability of the cell. (Roychowdhury & Sierra-Fonseca, 2017) In a degenerated neuron (lower
panel) MAP protein TAU unbinds MTs leading to NFT formation in the neuron. Amyloid Beta
plaques consists of several proteins including cytoskeletal proteins are found in extracellular
region (Šimić et al., 2016).
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1.3 Microtubule associated proteins, MAPs and Tau.
Microtubule dynamics in cells are regulated by various microtubule associated proteins (MAPs).
Tau belongs to MAPs family of proteins, which was identified in 1975, by Weingarten et al (Bai
& Burton, 2011) as a heat stable protein essential for microtubule assembly. Its role is important
for the stabilization of microtubules, and the cytoskeleton integrity. Tau is normally found in
axons. Aggregations of hyper phosphorylated Tau cause neurofibrillary tangles (NFT) (Fig.1)
(Nobel W.et al., 2013). The presence of NFTs are a hallmark of AD and other NDs. In normal
neuronal cells Tau will bind and stabilize MT. In abnormal neuronal cells Tau will disassociate
from the microtubules and aggregate in the cell body and dendrites. The abnormal deposition of
modified tau proteins in the neurons is a common aspect of many neurodegenerative disease
referred to as tauopathies. Tauopathies are a class of neurodegenerative diseases occur by hyper
phosphorylation and aggregation of the microtubule associated protein Tau, into paired helical
filaments or straight filaments, forming NFTs in the brain (Chu D., & Liu, 2019). In a study using
tau 441- transfected SHSY5Y human neuroblastoma cells, it was found, that hyperphosphorylated
tau protein disrupts normal synaptic transmission of neurons independently of neurodegeneration
or loss of synapse, suggesting that this is an early event in the progression of tauopathies (Löffler,
T. et al. ,2012). Specific hyperphosphorylation sites on TAU have been shown in AD brain. The
study confirmed high hyperphosphorylation of TAU at Ser396/Ser404/Thr181 as well as low
hyperphosphorylation at Thr231/Ser235/Ser202 (Modi et al., 2014). Pharmacological
interventions of tau phosphorylation are thought to present a new avenue in the treatment of
tauopathies. There is a total of six isoforms of tau, due to alternative splicing of tau (MAPT) gene
expressed in the adult human brain (Fig. 2) (Majounie et al., 2013).
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Figure. 2 The human Tau gene
The six isoforms of the human CNS tau protein. Alternative splicing of MAPT gene produces the
tau isoforms of 352-441 amino acids as indicated. Specific hyperphosphorylation sites on tau have
been shown in Alzheimer's brain. Although there is evidence that phosphorylation of individual
residues on tau significantly impacts its function; it remains to be established if the overall
phosphorylation state of tau or phosphorylation at specific residues is important in ND
pathogenesis (Majounie et al., 2013).

1.4 G protein-mediated signaling
G-proteins consist of several families of diverse cellular proteins that serve an equally
diverse selection of cellular functions. These proteins derive their name, from the fact that they
bind guanine nucleotides guanosine triphosphate (GTP) or guanosine diphosphate (GDP) and
possess intrinsic GTPase activity. G proteins play a central role in signal transduction by
transferring signals from cell surface receptor to intracellular effector molecules. (Gilman, 1987;
Dohlman et al., 1991; Siman et. al 1991; Neves et al., 2002; McCudden et al., 2005) Heterotrimeric
G-proteins consist of three elements, G-protein Coupled receptors (GPCRs), G Proteins and
effectors. GPCR are the largest family of transmembrane receptors along, with their role in signal
transduction. GPCRs regulate multiple physiological functions such as neurotransmission immune
5

system function, cell growth and proliferation, and hormonal signals. The involvement of GPCRs
in complex signaling throughout the body has made them a target for about 40% of modern drug
currently in the market. Despite their highly diverse nature all GPCRs consist of seven
transmembrane domains with three extracellular and three intracellular loops. The extracellular
domain is responsible for ligand binding and the intracellular domain is responsible for G-protein
binding (Dohlman et al., 1991; Latek et. al 2012). G Protein heterotrimers, consisting of guanine
nucleotide binding α plus βγ subunits, is inactive in cellular signaling. Agonist binding to GPCRs
triggers structural rearrangements in the receptors such that the intracellular domain then catalyzes
a nucleotide exchange in the α subunit of the heterotrimeric G proteins. Subsequently, activated
Gα changes its association with Gβγ in a manner that permits both subunits to participate in the
regulation of intracellular effector molecules (Fig.3). The typical effectors of G signaling include
adenylyl cyclase, phospholipase C, phospholipase A2, ion channels, and several kinases and
transcription factors. Among the effector molecules interacting with G are phospholipases, K+
and Ca2+ channels, GPCR kinases, members of the MAPK signaling pathway, monomeric G
proteins, regulators of G protein signaling (RGS proteins), and phosphoinositide-3 kinase (PI3K)
(Ueda et al., 1994; Wickman et al., 1994; Faure et al., 1994; Ford et al., 1998; Shi et al., 2001;
Smrcka, 2008). Thus, G protein  and  subunits are capable of activating diverse downstream
effectors. Termination of the signal occurs when the GTP bound to the G subunit is hydrolyzed
by the GTPase activity, causing the functional dissociation from the effector and reassociation with
the G subunit. Although G proteins are likely to membrane-bound when coupled to receptors,
recent results from various laboratories suggest that G proteins associate with MTs and regulate
assembly/dynamics of MTs and neuronal differentiation (Roychowdhury & Rasenick, 1997)
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1.5 G-protein signaling pathway, Microtubule assembly and neurite outgrowth
The dynamic process of Microtubule assembly must be tightly regulated in order to
accomplish the proper morphology and connectivity between neuronal cells. Microtubule
assembly can be regulated by different pathways. Previous studies from our laboratory have
indicated that MT assembly could be regulated by G-protein mediated signaling. As indicated in
Fig.3 , binding of the agonist to GPCR leads to an activation of G and G It is the Gcomplex
that has been shown to promote Microtubule assembly and induce neuronal differentiation (Fig.3)
(Roychowdhury and Rasenick 1997; Sierra-Fonseca et. al 2014). It was observed that
reconstructed heterotrimers, would not show signs of coupling with MTs nor take part in
modulating MT assembly, concluding that G proteins activation was necessary for G dependent
MT assembly (Fig.3) (Roychowdhury et. al 2006; Sierra-Fonseca et. al 2018). Using the antimiotic
drug nocodazale, it has been demonstrated that tubulin G interaction is important for MT
assembly in cultured PC12, NIH3T3 cells (Montoya et. al 2007). It was found that G-MT is
critical for Nerve growth factor (NGF) induced neuronal of PC12 cells. (Sierra-Fonseca et al.,
2014). Overexpression of G in PC12 cell in the absence of NGF produced neurites (SierraFonseca et al., 2014) While Gβγ-sequestering peptide GRK2i inhibited neurite formation,
disrupted MTs, and induced neurite damage; the Gβγ activator mSIRK stimulated neurite
outgrowth, which indicates the involvement of Gβγ in this process (Sierra-Fonseca et al., 2014).
These results suggest that the G initiated by the activation of the GPCR, interacts with
microtubules and this interaction is important for MT assembly and neuronal differentiation and
dysregulation of this process could lead to neurodegeneration. (Fig 3)
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Figure. 3 Gβγ signaling, MT assembly and Neurite outgrowth. Activation of GPCR
triggers the disassociation of the G heterotrimer into G and G subunits. These subunits
play a role in activation of several signaling pathways including adenylyl cyclase, phospholipases,
and PI3-Kinase pathways. It has been previously found from our laboratory that G subunit
interacts with tubulin heterodimers to stimulate microtubule assembly and to induce neurite
outgrowth in pheochromoctyoma (PC12) cells (Roychowdhury and Rasenick, 1997; Montoya et
al., 2007; Sierra-Fonseca et. al 2014).
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1.6 G signaling and PI3K/AKT/GSK3B pathway: Regulation of MT assembly and neurite
outgrowth
Although results from our laboratory indicate an important role of Gin NGF-induced
neuronal differentiation in PC12 cells (sierra-Fonseca et.al 2014), NGF is also known to induce
neurite outgrowth in PC12 cells by activating the receptor tyrosine kinase, TrkA [Knight et al.,
2006] and subsequent activation of downstream phosphatidylinositol 3-kinase (PI3K) pathway.
Two downstream effectors of PI3K that have been shown to participate in the regulation of neurite
outgrowth and are particularly associated with MT remodeling, are AKT (a serine/threoninespecific protein kinase) and the glycogen synthase kinase 3 (GSK-3) (Zhou et.al 2004; Zhou
and Snyder 2005, 2006; Dill et.al 2008). PI3K is known to phosphorylate and activate AKT, which
is followed, by phosphorylation and inactivation of GSK-3. Unlike AKT or many other kinases,
GSK-3 is usually active in resting cells. Upon activation of the PI3K signaling pathway, GSK3is inactivated through phosphorylation at the serine 9 residue in its amino terminal region
(Doble and Woodgett 2003). Phosphorylation of GSK3leads to inhibition of glycogen synthesis.
(Brunet, Datta & Greenberg, 2001). Recently GSK3 has emerged as an important signaling
mediator in the regulation of axon extension and axon branching by transducing downstream
signaling to reorganize axonal cytoskeleton and MTs. (Kim, Hur, Snider & Zhou, 2011). GSK3
dysregulation has been implicated in AD and PD. In AD, GSK3 is thought to attribute to
hyperphosphorylation of TAU. In a recent study TAU hyperphosphorylation was induced by
overexpressing GSK3 in SHSY5Y cell line (Cortez-Gomez et al.,2020). Another study
determined that dysregulation of GSK3 contributed to parkinsonian dopaminergic neuronal cell
death (Li, J et al, 2020). Recent studies suggest that the activation of PI3K/AKT pathway by NGF
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is, in part, mediated through the  subunit. (Wang & Wong, 2009). These findings correlate with
previous findings from our laboratory that G overexpression in PC12 cells was sufficient to
promote neurite outgrowth as well as increasing levels of PAKT/pGSK3. (Verela J, MS thesis
UTEP 2016) These findings suggest that the co-ordination of G and PI3K/AKT/GSK3 pathway
may regulate neurite morphology and outgrowth (Fig 4). Manipulation of the G and PI3K
pathway can help understand the regulation for neuronal differentiation and neurodegeneration
(Roychowdhury & Sierra-Fonseca 2017).

Figure. 4 G and PI3K signaling pathway in regulating MT assembly and neurite
outgrowth: A proposed Model. NGF acts through TrkA receptors to activatePI3K and its
downstream effectors Akt and GSK3 (left panel). The results from our laboratory demonstrate
the NGF utilizes G, a key component of the GPCR pathway (right panel), to alter MT assembly
and neurite outgrowth (central panel). PI3Ky is a downstream effector of G in GPCR signaling.
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G overexpression in PC12 cells was sufficient to promote neurite formation, as well as to increase
levels of PAKT and pGSK3.
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1.7 Gallein, Tideglusib, and Retinoic acid
Previous studies have used inhibitors to further understand the signaling mechanism,
interaction and function. Gallein (GAL), a small molecule found to bind to the G subunit with
high affinity blocking G dependent cellular activities. In a recent study GAL was used in
amphetamine induced cultured dopamine neurons. The study concluded that there is an interaction
between G and dopamine transporter (DAT) signaling. GAL has been shown to block Gdependent activation of the PI3K isoform (Mariana 2019). In a recent study using gallein, it was
found that APP-dependent toxicity is mediated by G complex signaling. p38MAPK was
identified as a downstream target of G complex (Bignonte, et al.,2019). Tideglusib (TIDE) , an
ATP non-competitive GSK-3β inhibitor from the tiadiazolidinone family, has been tested
clinically in several neurological disorders and was shown to reduce hyperphosphorylation of Tau.
It was tested in phase II clinical trial for the treatment of AD (Lovestone S. et al., 2015). Both GAL
and TIDE were used in the current study to further understand the mechanism by which G and
GSK3 are involved in the regulation of neurite outgrowth, MT assembly, and neurodegeneration.
Retinoic Acid (RA) is a vitamin A derivative known to possess powerful growth inhibiting and
cellular differentiation promoting properties. It has been used extensively in differentiation of
SHSY5Y cells. Usage of RA treatment for the differentiation of SHSY5Y leads to neurons
exhibiting more cholinergic properties since the differentiation induces the expression of
cholinergic markers (De Medeiros et al., 2019). Dysfunctions in cholinergic signaling have been
linked with the pathophysiology of several disorders and diseases, including depression,
schizophrenia, cancer, Huntington’s, Parkinson’s and Alzheimer’s disease (Madireddy &
Madireddy, 2019). RA has been shown to promote cellular differentiation and survival in SHSY5Y
cell line by utilizing the PI3K/AKT pathway. (Cheung et al., 2009). RA has been used in the
12

current study to differentiate SHSY5Y cells to further understand the mechanism of neuronal
differentiation by G.
1.8. Hypothesis and specific aims
The goal of this proposal is to determine the mechanism by which G interferes with
neuronal differentiation and induces neurodegeneration. G has been shown to play a critical
role in neuronal differentiation in NGF-differentiated PC12 cells through its interaction with
tubulin/MTs, and subsequent stimulation of MT assembly (Sierra-Fonseca 2013). Blocking the
interaction between G and MTs was shown to disrupt MTs and inhibit neurite outgrowth,
suggesting a role of G in neurodegeneration, More recently, PI3K/PAKT/GSK3 pathway was
shown to be involved in G dependent regulation of MTs and neurite outgrowth (Varela J, MS
thesis, UTEP 2016). In the present study we will address this issue using neuronal cells SHSY5Y.
I hypothesize that G is involved in neurodegeneration by disrupting MTs, inducing
hyperphosphorylation of tau proteins, and altering G-mediated downstream signaling
pathway. We plan to test our hypothesis by focusing on the following aims in this study.
Specific Aim-1: Determine the role of G in MT disruption, degeneration of neurites, and tau
phosphorylation.

Specific Aim-2: Delineate the mechanism of G-dependent microtubule disruption/neuronal
damage by downstream PI3K/pAKT/pGSK3 pathways.
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Chapter 2: Materials and Methods
2.1. Cell culture and RA Treatment for SHSY5Y
Human neuroblastoma cells SHSY5Y cells were grown in T-25 or T-75 culture flasks at 37ᵒC in
Dulbecco’s modified of Eagle’s medium (DMEM)/Ham’s F-12 50/50 mix (DMEM/F-12 50/50),
supplemented with 10 % fetal bovine serum and penicillin (100U/mL)-streptomycin (100um/mL) in
5% CO2. For Retinoic acid treatment cells where grown in 10M RA (stock 10 mM) diluted in
DMSO, 2.5% FBS, 1% penicillin and 2mM Glutamic acid (stock 20mM) per ml.
2.2 Preparation of whole cell lysates
SHSY5Y cells were grown under the conditions described in section 2.2. For Gallien treatment,
cells were grown on 100 mm culture dishes until they reached ~80% confluence. Cells were treated
with the drug (10 μM) for 4 hours. Whole cell lysates were also prepared. After treatment culture
media was removed, cells were washed with PBS, and then lysed by incubation in 500 µL lysis
buffer (10 mM Tris-HCl, pH 7.9, 1.5 mM MgCl2, 0.3 M sucrose, 0.1% Triton X-100, 1 mM DTT,
and 10 µM GTP) supplemented with protease inhibitor cocktail, for 10 min at room temperature.
Cells were then scraped and sonicated for 1 min, followed by centrifugation at 10,000 × g for 10
min. The supernatants constituted whole cell lysates, and the protein concentration was determined
by the Bradford assay.
2.3 Electrophoresis and immunoblotting
Samples for immunoblotting were subjected to SDS-polyacrylamide gel (10%) electrophoresis,
followed by ElectroTransfer onto nitrocellulose membranes (find distributer). The membranes
were blocked in 5% nonfat dry milk in TBS (10 mM Tris-HCl and 150 mM NaCl, pH 7.4) for 2 h
at room temperature, followed by overnight incubation at 4 °C with mouse monoclonal anti-tubulin
14

, rabbit polyclonal anti-Gβ (check company check ratio), or rabbit monoclonal anti-AKT and antipAKT (Cell Signaling Technology, 1:500) antibodies in TBS containing 0.01% BSA. The
membranes were washed three times with 0.05% Tween-20 in TBS (TBST) and incubated with
the appropriate Conjugated secondary antibodies (goat anti-mouse or goat anti-rabbit, or donkey
anti- goat from check ratio check man..) in TBST containing 0.01% BSA for 1 h. For sensitive
detection, the chemiluminescence (ECL) technique (check how it was made we make it but where
do we get the reagents) was used according to the manufacturer’s instructions. Quantitative
analysis of the protein bands was performed with the I-Bright image acquisition and analysis
software (who make I-bright where is the software from).
2.4 Immunoprecipitation
For immunoprecipitation experiments, 100 µL aliquots of cellular fractions (~0.25–1 mg/mL of
protein) were incubated with or without anti-Gβ antibody (5-10 µl), or non-specific rabbit IgG for
1 hr at 4 °C, followed by an overnight incubation (4 °C) with 100 µL of 50% protein A-sepharose
(where did we get the beads), Samples were then centrifuged at 10,000 × g for 10 min, and the
supernatants (SUP) were saved. The pellets (immunocomplex) were washed with PBS and eluted
with 3% SDS Laemmli sample buffer containing 0.15 M dithiothreitol (DTT) and boiled in a water
bath for 5 min. Samples were then clarified by centrifugation. Both IP and SUP fractions were
then subjected to immunoblotting using anti-tubulin or anti-actin antibodies as described in section
2.3
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2.5 Immunofluorescence and confocal microscopy
For confocal microscopic analysis, cells were attached to immunocytochemistry slides seeded on
glass coverslips using 12-well plates and were grown overnight as described in section 2.1. Cells
were then treated with or without RA and/or inhibitors as indicated and subsequently fixed by the
addition of ice-cold 100% methanol (previously cooled to -20 °C) and incubated at -20 °C for 5
min (). The cells were then rinsed three times in PBS, blocked for 1 h at room temperature in 5%
normal goat serum (NGS) (Sigma-Aldrich) in PBS, followed by overnight incubation at 4 °C with
primary antibodies (anti-tubulin, anti-Gβ, and anti-tau1:100 dilution) in 1% NGS in PBS.( check
primary and secondary) The slides were rinsed as before and incubated with the appropriate
secondary antibodies (tetramethyl rhodamine (TMR)-conjugated goat anti-mouse IgG,
AlexaFlur488-conjugated goat anti-mouse IgG, Alexa Fluor 647-conjugated donkey antirabbitIgG; for 2 h at room temperature in the dark to diminish photo-bleaching effects. The slides
were then mounted with DAKO mounting media (DAKO Corporation, Carpenteria, CA), or with
ProLong Gold anti-fade reagent with DAPI (Invitrogen, for nuclear staining), and covered with
coverslip. High-resolution, digital, fluorescent images were captured by employing inverted,
confocal laser-scanning microscopy (model LSM 700; Zeiss, Thornwood, NY), utilizing a PlanApochromat 63x/1.40 immersion-oil DIC objective and assisted with 2009 ZEN software (Zeiss,
Thornwood, NY). DAPI and Alexa Fluor 350 (blue), FITC (green), and TMR (red) were excited
with laser emissions of 405-, 488-, and 555-nm wavelengths.
2.6 Differential nuclear staining (DNS) assay for cytotoxicity
To determine the levels of cytotoxicity caused by the experimental compounds a previously
described DNS assay adapted for high-throughput screening was used (Lema et al., 2011). This
assay uses two fluorescent nucleic acid intercalators, Hoechst 33342 (Hoechst) and propidium
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iodide (PI). SHSY5Y cells were seeded in a 96-well plate format and incubated with GAL
inhibitor. One hour before image capturing, a staining mixture of Hoechst and PI at a final
concentration of 1 μg/mL for each dye was added to the cells. Subsequently, cells were imaged in
live-cell mode using a BD Pathway 855 Bioimager system (BD Biosciences, Rockville, MD).
Montages (2x2) from four adjacent image fields were captured per well to acquire an adequate
number of cells for statistical analysis, utilizing a 10x objective. To determine the percentage of
dead cells from each well, both image acquisition and data analysis were performed using the BD
AttoVision v1.6.2 software (BD Biosciences), and each experimental condition was assessed with
8 replicates.
2.7 Preparation of inhibitor
GAL was purchased from Sigma Aldrich CAS 2103-64-2. GAL was diluted in DMSO as
instructed by manufacturer. GAL stock concentration is 12.5 mM after dilution in 1ml of DMSO.
To dilute GAL concentration to 10 uM 3.2 ul of original stock / 4 ml of DMEM media.
Tideglusib was purchased from Sigma Aldrich CAS 865854-05-03. Tideglusib was diluted in
DMSO as instructed by manufacturer. Final stock concentration of Tideglusib is 30 mM. To bring
Tideglusib concentration to 10 uM by diluting 3.33 ul of 30 mM stock per 10 ml of DMEM media.
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Chapter-3: Results

3.1 Specific Aim-1: Determine the role of G in MT disruption, tau phosphorylation, and
degeneration of neurites,
3.1.1 Objective and overview
We have shown previously that  subunits of heterotrimeric G proteins promote MT assembly in
vitro and in cultured PC12 cells (Roychowdhury 1997; Montoya 2007). Recently, we found that
the interaction of G with tubulin and MTs were increased during NGF-induced neuronal
differentiation of PC12 cells. In addition, the sequestration of Gby GRK2i, a G-inhibitory
peptide, inhibited neurite outgrowth, disrupted MTs and induced cellular aggregation (Sierra
Fonseca 2014), thus, indicating a possible role of Gin neuronal disruption and inducing
neurodegeneration. Since PC12 cells are non-neuronal cells, in this aim we will determine if Gtubulin/MT interaction occurs in neuronal cells SHSY5Y, and whether blocking this interaction
leads to MT disruption and neuronal damage as observed in PC12 cells. We will use gallein
(GAL), a small molecule inhibitor of Gwhich is known to inhibit G-dependent cellular
activities, to conduct this study. SHSY5Y cells are a neuroblastoma derived cell line that is
commonly used in vitro to further understand the process of neurodegeneration (ND). SHSY5Y
cells were further differentiated in the presence RA, into a more mature neuron-like phenotype
that is characterized by neuronal markers. The goal of this aim is to determine the role of G in
MT disruption, and neuronal damage in neuronal cells SHSY5Y. Specifically, we will determine
if blocking G by gallein (GAL), an inhibitor of G, interferes with G-tubulin interaction, MT
organization and neurite formation. Tau hyperphosphorylation, which is a signature event occurs
during neurodegeneration will also be examined in the presence of GAL.
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3.1.2 Results:
Gallein disrupts MT organization and inhibits neurite formation in SHSY5Y cells:
To test the effect of GAL on neurite formation and MT assembly/organization,
immunofluorescence and confocal microscopic analysis were carried out (Sierra-Fonseca 2014).
Briefly, SHSY5Y cells were attached to cover slips placed in 12 wells plate (25000 cells/well).
The samples were then treated with 1uM, 5uM, or 10M GAL for 1h, and processed for confocal
microscopy as described in the methods. MT organization and neurite outgrowth were examined.
G (red) was colocalized with MTs in the cell body and neuronal processes in control SHSY5Y
cells (Fig. 1A). As the concentration of GAL increases, neurite formation is inhibited, the
disruption of MTs is increased, and MT assembly/organization was drastically disrupted as evident
by the tubulin staining (green). G becomes localized more towards the ends of the neurites as
evident by Gstaining (red) where tubulin immunoreactivity was not observed. This is consistent
with the recent observation that Gwas found to be colocalized with actin filaments at the distal
end of the neurites and growth cones (Sierra-Fonseca, 2021). The neurites begin to thin as the
concentration of GAL increase. At 1M GAL the neurites resemble control neurites, only slightly
thinner. At 5M GAL, the filaments are thinner than both control and in the presence of 1M
GAL, but still connected to the cell body of the neuron. Neurite formation was inhibited at 10 M
GAL. The neurites become very thin causing it to break off from the cell body of the neuron
(Fig.5). MT assembly/organization was drastically disrupted as evident by the tubulin staining
(green). Both MTs and G localization was disrupted by GAL suggesting a clear relationship
between Gand MT organizations. In addition to SHSY5Y cells, we tested the effect of GAL in
RA-differentiated SHSY5Y cells. As shown in Fig.6. RA induced differentiation of SHSY5Y cells
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which is exhibited by stabilized neuronal processes and interconnectivity among neurons. We
found that similar damaging effect of GAL in RA-differentiated SHSY5Y cells treated with 10
M GAL (Fig.6). When both SHSY5Y cells and RA-treated SHSY5Y cells were incubated with
10 M GAL for 72 hours, it was observed that GAL caused the cells to aggregate in both treatment
groups. Loss of neurites were evident in both SHSY5Y and differentiated SHSY5Y (Fig 5 & Fig
6).
.
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Figure 5. Effect of GAL on MTs and G organization, and neurite formation.
SHSY5Y were seeded on glass coverslip in 12 well plate at a density of 35,000/well. Once cells
fully adhered GAL treatment was administered at a concentration of 1M, 5M, or 10M for 1h
(A) or 72h (B). The cells were then fixed and double labeled with Alexa-Fluor 488 conjugated
anti-tubulin (1-100 dilution) (green) and Alexa-Fluor 546 conjugated anti-Gβ (red) antibodies
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(1:100 dilutions) as indicated in the methods. Nucleus was labelled with DAPI (blue). Areas of
overlay (merge) appear yellow.
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Figure 6. GAL disrupts MT assembly in RA differentiated SHSY5Y
SHSY5Y Cells were treated with 10 M RA for 3 days or until visible differentiation occurred.
Subsequently, cells were treated with or without 10 M GAL and processed for confocal
microscopy using Alexa-Fluor 488 conjugated anti-tubulin (1-100 dilution) (green and AlexaFluor 546 conjugated anti-Gβ (red) antibodies (1:100 dilutions) as indicated in the methods.
Nucleus was labelled with DAPI (blue). Areas of overlay (merge) appear yellow.
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GAL inhibited G expression in both SHSY5Y and RA-differentiated SHSY5Y cells while
tubulin expression was not affected by GAL.
Because GAL affected MT/G organization, and neurite formation in both SHSY5Y and RAdifferentiated SHSY5Y cells, I tested the effect of GAL on tubulin and G (G) expression in
these cells. SHSY5Y cells were seeded on 100 mm plates. SHSY5Y cells were prepared for RA
differentiation. Cells were treated with 10 uM RA for three days or until visible differentiation
occurred. Both control and RA-differentiated cells were treated with GAL for one hour. Wholecell lysates were prepared as indicated in the methods, subjected to gel electrophoresis followed
by immunoblotting with anti-Tubulin and anti-G antibodies. Protein bands were detected using
the ECL-plus reagent, quantitated, and expressed as percent control. As shown in the figure 6,
GAL did not alter tubulin expression significantly, but the expression of Gappears to be inhibited
in the presence of GAL both in SHSY5Y and RA-differentiated SHSY5Y
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Figure.7 Effect of GAL on G and tubulin expression in SHSY5Y and differentiated
SHSY5Y cells.
SHSY5Y cells were seeded on 100 mm plates. SHSY5Y cells that were prepared for
differentiation were treated with RA for 3 days or until differentiation was visible. Cells were
then treated with 10 M GAL. Cells were then prepared for WCL and IB analysis. Anti-Tubulin
(Fig.7A) and Anti-G (Fig.7B) were used to incubate IB overnight. Protein bands were detected
by ECL plus reagent. Protein analysis was done using iBright fl100, statistical analysis was done
using Sigma plot. One-way anova analysis was performed on 5 experiments showed a p-value of
0.034 of tubulin expression of all treatment groups when compared to control.
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Tau expression was reduced in the presence of GAL
Since Tau is a microtubule-associated protein found in axons and known to regulate MT assembly
and neurite outgrowth, I examined whether the tau protein is affected by GAL. Specifically I
determined whether Tau expression is altered in the presence of GAL. Both SHSY5Y cells and
RA-differentiated SHSY5Y cells were used for this experiment. Cells were seeded in 100mm

plates, followed by treatment with GAL as indicated in the figure (Fig, X). Whole-cell lysates
(WCL) were prepared, and subjected to immunoblotting using Tau-specific antibodies.

Tau

expression in SHSY5Y cells was found to be slightly decreased in the presence of GAL. However,
in RA-differentiated cells, Tau expression was significantly decreased in the presence of GAL.
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Figure 8. GAL decreases TAU protein expression in SHSY5Y cells and differentiated SHSY5Y
cells.
SHSY5Y cells were plated in 100 mm. Subsequently, cells were treated with 10uM RA until
differentiation followed by GAL for 1 hour. Equal amounts of proteins from each sample were subjected
to immunoblot analysis using the anti-Tau antibody as indicated. Protein bands were detected using the
ECL-plus reagent, quantitated, and expressed as indicated in the figure. The experiment was repeated

three times with duplicates and statistical analysis was carried out using one-way ANOVA.
Controls represent 100%. Tau expression was decreased after GAL.T-test Analysis of 5
experiments showed statistical significance of p=0.004 between CON and GAL in Tau
expression; Statistical Significance of 3 experiments p=.033 in Tau expression was found in RA
and GAL.
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GAL decreases phosphorylation of TAU in the SER site 396
Since the hyperphosphorylation of tau is a signature event of neuronal damage and
neurodegeneration, and GAL has been shown to affect Tau expression, I determined if GAL
changes the phosphorylation status of tau. The tau protein has 70 potential phosphorylation sites
that almost span the entire protein structure. Based on the literature, several phosphorylation sites
are known to be pathologically relevant. We tested the effect of GAL on the phosphorylation of
tau at Ser396 using anti-ps396 Tau. Both SHSY5Y cells and RA-differentiated SHSY5Y cells
were used for this study. After treatment with GAL for one hour, whole-cell lysates were subjected
to immunoblotting with anti-ps396 Tau (abeam). Protein bands were detected using the ECL-plus
reagent, quantitated, and expressed as percent control. As indicated in the figure (Fix), GAL
decreased the expression of phosphorylated Tau in both SHSY5Y and RA-differentiated SHSY5Y
cells.
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Figure 9. GAL on phosphorylation of TAU in the SER site 396 in SHSY5Y and
differentiated SHSY5Y cells
SHSY5Y Cells where seeded on 100 mm plates. SHSY5Y cells that were prepared for
differentiation were treated with RA for 3 days or until differentiation was visible. Cells were
then treated with GAL one-hour followed by WCL extraction and immunoblotting using antips396 TAU. Protein detection was done using ECL plus reagent. Quantification and analysis
were done by I-bright fl1000. Statistical analysis was performed by Sigma plot. T-test Analysis
of 6 experiments showed statistical significance of p=0.042 between CON and GAL in ps396
Tau expression; Statistical Significance of 4 experiments p=.025 in ps396 Tau expression was
found in RA and GAL.

29

3.2 Specific Aim-2: Delineate the mechanism of G-dependent microtubule disruption/neuronal
damage by downstream PI3K/pAKT/pGSK3 pathways.

3.2.1 Objective and overview
The goal of this aim is to determine the signaling pathway by which G interferes with MT
assembly and neurite outgrowth, and induces neurodegeneration. One of the downstream effector
of G, which is known to known to participate in the regulation of neurite outgrowth and MT
assembly is Phosphatidyl inositol-3-kinase (PI3K). Activation of PI3K has been shown to promote
the phosphorylation of downstream AKT and GSK-3β, which subsequently participate in the
regulation of neurite outgrowth, and are particularly associated with microtubule remodeling. It
has been shown earlier from our laboratory that the overexpression of G in PC12 induces neurite
outgrowth (Sierra-Fonseca et al.,2014 ) and phosphorylate Akt and GSK3 supporting the notion
that G and PI3K pathway co-ordinate to regulate neurite outgrowth. Therefore, in the current
aim, I will dissect the interplay among G, GSK3, and MTs in inducing neurodegeneration. G
inhibitor gallein, and GSK3 inhibitor tideglusib will be used to conduct the study. Because over
activation of GSK3, has been shown to play key roles in tau hyperphosphorylation, we will
determine if GAL or tideglusib interferes with Tau phosphorylation.
The Following sub aims will be addressed

1) Determine how GAL and/or tideglusib interferes with the phosphorylation of Akt and GSK3
in SHSY5Y cells.
2) Does tideglusib interferes with G localization/expression and neurite formation?
3) How does GSK3 inhibitor affect expression of TAU, and ps396 TA
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3.2.2 Results:
G and GSK3 inhibitors decrease phosphorylation of Akt and GSK3
To examine the increasing effect of gallein and tideglusib SHSY5Y cells were treated with
inhibitors at 1M, 5M, and 10 M concentrations for one hour. Previously I found Gdecreased
phosphorylation of Akt and GSK3. I wanted to see the effect GAL had at a lower concentration
on these molecules. At 1 M GAL slightly decreased phosphorylation Akt and had a greater
decrease of expression of GSK3M GAL had slightly greater decreasing effect of expression
of molecules. A confocal experiment done in this study showed that SHSY5Y cells treated with 1
M GAL morphology was similar or better then control. Previous studies have suggested that
GAL may have a positive effect on MT dynamics (Bignante, E., et al., 2018). To further understand
G signaling involvement with PI3K/AKT/GSK3 signaling pathway in MT assembly and
organization; SHSY5Y cells were treated with 5 M and 10 M Tideglusib. Inhibition of GSK3
lead to a decrease of both pAKT and pGSK3. Inhibition of GSK3 is thought to promote MT
assembly (Noble, W., et al, 2013). Previous studies from our laboratory have shown that pGSK3
is increased in Goverexpressed cells (Sierra-Fonseca, et al.,2014). Suggesting G may have a
direct effect on GSK3
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Figure 10. Increasing Concentrations of G and GSK3 inhibitors leads to decreasing
expression of pAKT and pGSK3
Inhibition of G and GSK3lead to a decrease expression of pAKT and pGSK3 in SHSY5Y
cells. SHSY5Y cells were plated in 100 mm. Once cells fully adhered treatment of GAL and
Tideglusib at varying concentrations (1M,5M, and 10M) was administered. Whole-cell lysates
were prepared for western blot as described in the methods. Equal amounts of proteins from each
sample were subjected to immunoblot analysis using an anti-pAKT and anti-pGSK3 antibody as
indicated. Protein bands were detected using the ECL-plus reagent, quantitated, and expressed as
indicated in the figure above. One way anova analysis using sigma plot software showed a p=.005
for pGSK3b expression for all concentrations of GAL n=4.
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3.2.3 Results:
Tideglusib interferes with MT organization and alters neurite formation in SHSY5Y cells:
To test the effect of TIDE, on neurite formation, MT assembly/organization, and localization/colocalization of G and MTs, immunofluorescence and confocal microscopic analysis were carried
out as described before (Sierra-Fonseca 2014). Briefly, SHSY5Y cells were attached to cover slips
placed in 12 wells plate (25000 cells/well). The samples were then treated with 10M GAL for
1h. MT organization and neurite outgrowth were examined. As shown in the Fig.10, neurite
formation was altered by TIDE. Cells became aggregated. MT assembly/organization was
disrupted as the concentration of TIDE increased as evident by the tubulin staining (green). G
(red) was co-localized with MTs in the cell body and neuronal processes in control SHSY5Y cells.
Both MTs and G localization was disrupted by TIDE suggesting a clear relationship between
TIDE a GSK3 inhibitor and Gin MT organizations. In addition, the additive/synergistic effect
of GSK3 inhibitor and GAL was tested to delineate G and GSK3 mechanism in MT assembly
and organization. Fig.11. Neurites formation was inhibited in both low and high combined
concentrations of inhibitors as evident by the tubulin staining (green). At the lower combined
concentration of inhibitors, the nucleus staining (blue) shows the nucleus swollen when compared
to control. At the higher concentration the combined effect of GAL and TIDE shows some change
in the nucleus staining (blue). G staining (red) localization in both treatments is evident at the
ends of the process near the growth cone. Further indicating G involvement in MT assembly.
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Figure 11. GSk3 inhibitor alters neurites and G expression in SHSY5Y
SHSY5Y were seeded on glass coverslip in 12 well plate at a density of 35,000/well. Once cells
fully adhered Tideglusib treatment was administered at a concentration of 5M, or 10M for 1h.
The cells were then fixed and double labeled with Alexa-Fluor 488 conjugated anti-tubulin (1-100
dilution) (green) and Alexa-Fluor 546 conjugated anti-Gβ (red) antibodies (1:100 dilutions) as
indicated in the methods. Nucleus was labelled with DAPI (blue). Areas of overlay (merge) appear
yellow.
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Figure 12. Combined inhibition of G and GSK3 leads to neuronal disruption.
SHSY5Y were seeded on glass coverslip in 12 well plate at a density of 35,000/well. Once cells
fully adhered combined treatment of Gallein and Tideglusib treatment was administered at
concentration of 1M, or 10M for 1h. The cells were then fixed and double labeled with AlexaFluor 488 conjugated anti-tubulin (1-100 dilution) (green) and Alexa-Fluor 546 conjugated antiGβ (red) antibodies (1:100 dilutions) as indicated in the methods. Nucleus was labelled with DAPI
(blue). Areas of overlay (merge) appear yellow.
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G and GSK3 inhibitors lead to a decrease of phosphorylation of Tau at serine 396 site in
SHSY5Y cells.
In previous preclinical studies, tideglusib was reported to reduce a range of disease outcomes,
including tau phosphorylation, amyloid deposition, neuron loss, and gliosis in mouse entorhinal
cortex and hippocampus, and to reverse a spatial memory deficit in transgenic mice.
Neuroprotective, anti-inflammatory, and neurogenesis-inducing effects of tideglusib have been
reported in animal models, as well. (Sereno et al., 2009; Morales-Garcia et al., 2012, Wang et al.,
2016). In our current study Inhibition of G lead to a decrease of Tau phosphorylation in
SHSY5Y and differentiated SHSY5Y cells. Similarly, Tideglusib also reduced the expression of
ps396 tau in SHSY5Y. As previously mentioned, a study on mice concluded that Amyloid
Precurser protein/Go protein G complex signaling mediates Ab degeneration and cognitive
impairment in AD models (Bignante, E. A., et al.,2018) Thus, indicating G inhibition may also
have a positive effect on Tau phosphorylation, NFT, amyloid deposition, and neuronal loss.
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Figure 13. Increase in the concentrations of G and GSK3 inhibitors lead to a significant
decrease of phosphorylation of Tau at serine 396 site in SHSY5Y cells.
Inhibition of G and GSK3lead to a decrease expression of ps396 TAU in SHSY5Y cells.
SHSY5Y cells were plated in 100 mm. Once cells fully adhered treatment of GAL and tideglusib
at varying concentrations (1M,5M, and 10M) was administered. Whole-cell lysates were
prepared for western blot as described in the methods. Equal amounts of proteins from each sample
were subjected to immunoblot analysis using an anti-ps396 antibody as indicated. GAPDH was
used as a loading control anti-GAPDH was used. Protein bands were detected using the ECL-plus
reagent, quantitated, and expressed as indicated in the figure above. One way anova analysis using

37

sigma plot software showed a p=.001 for ps396 Tau expression for all concentrations of GAL and
tideglusib n=4.
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The effects of Tideglusib on RA differentiated SHSYSY.
In our current study to further understand how inhibition of GSK3affects neuronal differentiation
and MT assembly Tideglusib was used in RA differentiated SHSY5Y cells. Surprisingly, in the
presence of RA Tideglusib increased phosphorylation of Akt, GSK3, Tau. It also increased
expression of Tau and G. Previous results from our laboratory indicated that NGF
differentiation, and overexpression of G in PC12 cells lead to an increase of pGSK3(Varela J,
MS thesis, UTEP 2016).

RA is thought to bind TrkB receptor to phosphorylate

AkT/GSK3signaling pathway to induce further differentiation in SHSY5Y cells (Masia S., et al.,
2007). NGF binds to TrkA receptor activating the PI3K/AkT/GSK3 signaling cascade, to
promote neuronal differentiation of PC12 cells. Tideglusib inhibition of GSK3 is thought to lead
to pGSK3 promoting MT assembly (Greene, L. A., & Tischlert, A. S,1976). Surprisingly our
study saw that Tideglusib not only increases phosphorylation of AKT and GSk3, but
phosphorylated Tau as well. Phosphorylation of Tau is thought to contribute to Tau hypothesis of
ND pathology (Morales-Garcia J.A., et al.,2012). Indicating that up regulated promotion of
inhibition of GSK3 may not be ideal to treating ND.
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Phosphorylation of Akt and GSK3are not significantly affected by Tideglusib in RADifferentiated SHSY5Y cells
To further understand Gsignaling involvement with PI3K/AKT/GSK3Tideglusib was used
to treat RA differentiated cells. Tideglusib is known to increase phosphorylation of GSK3.
Dysregulation of GSK3 is attributed to tau hyperphosphorylation. In a recent study
overexpression of GSK3 lead to increase in the phosphorylation of Tau and GSK3 modulated
acetylcholinesterase expression (Cortés-Gómez, M. et al., 2020). As previously mentioned, RA
differentiated SHSY5Y cells express cholinergic markers. Gallein had a decrease of expression in
pGSK3 and no change in pAKT. Indicating may have a G direct effect on phosphorylation of
GSK3.
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Figure 14. Effect of GSK3 inhibitor on the phosphorylation of AKT and GSK3 in RA
differentiated SHSY5Y cells 
Effect of TIDE on the expression of pAKT and pGSK3 in differentiated SHSY5Y. SHSY5Y
cells were plated in 100 mm. Subsequently, cells were treated with RA at 10 uM until
differentiated, TIDE at 10uM, one hour after cells treated for differentiation occurred. Wholecell lysates were prepared for western blot as described in the methods. Equal amounts of
proteins from each sample were subjected to immunoblot analysis using an anti-pAKT and antipGSK3 antibody as indicated. Protein bands were detected using the ECL-plus reagent,
quantitated, and expressed as indicated in the figure above.
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Inhibitor of GSk3 increases expression of Tau, ps396 Tau, and Gin RA-differentiated
SHSY5Y cells
Dysregulation of GSK3 is believed to lead to phosphorylation of Tau. Tideglusib increased
expression Tau in SHSY5Y and differentiated SHSY5Y. Indicating that inhibition of GSK3 leads
to an increase of expression of TAU. This finding in my study resonates previous studies indicating
Tideglusib positive effect on Tau protein expression. In preclinical studies Tideglusib had a
neuroprotective effect in animal models. Tideglusib failed in phase II human clinical trial. GSK3
inhibition in differentiated SHSY5Y cells lead to an increase in the phosphorylation of Tau at
serine 396 site. Hyperphosphorylation of Tau at serine 396 site is thought to attribute to AD
pathology by inducing tau aggregations, leading to NFT. In our current study inhibition of GSK3
lead to an increase in tau phosphorylation in RA differentiated SHSY5Y cells. As previously
mentioned, RA is thought to induce differentiation by binding to TrkB receptor. Binding to
receptor leads to cascading signal activation of PI3K/Akt/GSK3 pathway. Tideglusib is known
to inhibit phosphorylation of TAU in mice studies. Few studies were done on human neuronal cells
with Tideglusib. Tideglusib increased Gexpression in SHSY5Y differentiated cells. Simiallerly
our lab showed that NGF differentiated PC12 cells increased expression of G (SierraFonseca,2014). NGF is thought to cause neuronal differentiation by PI3K/AKT/GSK3pathway
by binding to TRkA receptor (Greene, L. A., & Tischlert, A. S. 1976) Our laboratory showed the
PC12 cells overexpressing G lead to neuronal differentiation and increased expression of
pGSK3 (Varela J, MS thesis, UTEP 2016). Inhibition or promotion of G could regulate
GSK3. Gallein a G inhibitor decreased phosphorylation of Tau in both SHSY5Y and
differentiated SHSY5Y. Gallein decreased Tau expression. It is possible that G is needed to
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regulate GSK3 neuroprotective role as well as MT assembly and organization. (Sereno et al.,
2009; Morales-Garcia et al., 2012, Wang et al., 2016).
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Figure 15. Tideglusib in retinoic acid differentiated SHSY5Y leads to an increase of
expression of Tau, ps396 Tau, and G.
Tau expression decreased in SHSY5Y cells and in differentiated SHSY5Y treated with
Tideglusib. SHSY5Y cells were plated in 100 mm. Subsequently, cells were treated with RA at
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10 uM until differentiated, TIDE at 10uM, one hour after cells treated for differentiation
occurred. Whole-cell lysates were prepared for western blot as described in the methods. Equal
amounts of proteins from each sample were subjected to immunoblot analysis using an anti-Tau,
anti-ps396Tau, and anti-G antibody as indicated. Protein bands were detected using the ECLplus reagent, quantitated, and expressed as indicated in the figure above.
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Gallein does not induce neuronal cell death in SHSY5Y cells
To determine if Gallein induced neuronal cell death at the concentrations used, cytotoxicity assay
was performed. This assay uses two fluorescent dyes —Hoechst, which is membrane-permeable
and stains the nuclei of both living and dead cells, and propidium iodide (PI), which is only able
to enter cells with compromised plasma membranes, thus selectively staining the nuclei of dead
cells.
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Figure 16. Gallein Dose not induce cell death.
Cytotoxicity was performed using the BD AttoVision v1.6.2 software (BD Biosciences), and each
experimental condition was assessed with 8 replicates.. SHSY5Y were seeded on a 96-well plate
at a density of 10,000 cells per well and placed in 5% CO2 water jacket incubator at 37 degree
Fahrenheit. Cells where then treated with dyes Hoschet (penetrates cell membrane in viable cells)
and Pi ( penetrates dead cells membrane) for 1 hour along with Gallein.
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Chapter 4 Discussion:
Our laboratory has previously shown that G promotes MT assembly and induces neurite
outgrowth in NGF-differentiated PC12 cell. The interaction between G and TUB was increased
in the presence of NGF. Blocking the interaction by Grk2i, a G inhibitory peptide disrupted
MTs and inhibited neurite outgrowth.

Furthermore, overexpression of G prompted neurite

outgrowth in the absence of NGF. These results clearly suggested a role of G in
neurodegeneration. In the current study, Gallein, a small molecule inhibitor of G, was found to
inhibit neurite outgrowth, and disrupt MTs both in SHSY5Y and RA-differentiated SHSY5Y cells.
The results from microscopic analysis (Fig. 5) indicate that as the concentration of GAL increases
colocalization of TUB/Gdecreases, with G gradually moving towards the neurite ends and in
many cells G is solely found in the ends of the neurites at the growth cone. At 10 M GAL the
neurites start to cut off, some neurons have completely lost their process, and many cells were only
stained in blue (DAPI) suggesting that MT structure is completely lost. Since G is known to
binds to MTs and stabilize MTs and neurites, the result indicates that G association with MTs
and its localization are disrupted by increasing concentration of GAL leading to its release from
the cell body as well as from neurites allowing disruption of MTs. thinning of neurites and
eventually loss of neurites, and cellular aggregation. Similar results were observed in RAdifferentiated SHSY5Y cells (Fig.6) where GAL disrupted MT assembly, induced loss of neurites
and cellular aggregation.
Recently, GAL has been shown to inhibit amyloid- (A)-induced dendritic and axonal
dystrophy, abnormal tau phosphorylation, synaptic loss, and neuronal cell death in hippocampal
neurons, and reversed the memory-impairment in mice (Bigante et. al 2018). This study appears
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to contract our results which indicates that GAL induces MT disruption and inhibits neuronal
differentiation. However, it is likely both data sets are correct, and caution should be taken to
interpret the results. In our study we used 1h incubation with GAL while 30 min incubation with
GAL was used in earlier studies. Previously, we also used 30 min incubation with GAL, and found
that GAL stimulated neurite outgrowth slightly (Sierra-Fonseca PhD dissertation, UTEP, 2013).
Because we demonstrated earlier (Sierra-Fonseca 2014) that G (which is the target for GAL)
stimulated MT assembly and induced neurite outgrowth, we increased time for incubation with
GAL from 30 min to 1h to determine if cells exposed with GAL for a longer period of time is able
to disrupt MT network and neurite outgrowth. As expected, we found that neurite outgrowth as
well as MT assembly was disrupted by 1h incubation with GAL (Figs.5 and 6). Thus, it likely that
when cells were exposed minimally with GAL, it was able to influence multiple effector systems
(which includes adenylyl cyclase, phospholipases, ion channels, and PI3K) regulated by Gbg, and
positively influence neuronal cell differentiation. However, the result presented here clearly
indicates that GAL has the ability to directly modulate MTs and neurite formation, and should be
taken into account when examining the effect of GAL.
In this study, we found TIDE (Tideglusib) , an inhibitor of GSK3 also disrupted MTs and
inhibited neurite formation similar to that observed with GAL. The relationship between G and
GSK3 has been shown earlier. Overexpression of G has been shown to phosphorylate GSK3
(Jose Varela, Thesis UTEP 2016). Confocal analysis indicate that the nucleus of SHSY5Y cells
treated with a GSK3 inhibitor appeared swollen. Recently, Tideglusib was in clinical trial against
AD, and the trial was failed. Tideglusib was selected mainly based on studies done on mice. Our
results clearly indicate the damaging effect of Tideglusib on MTs and neurite formation in cultured
neuronal cells, and could be the reason why it was not successful in clinical trial. It should be noted
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that before Tideglusib was chosen for clinical trial, hardly any studies utilizing confocal analysis
were done to see how TIDE affected the morphology of human neuronal cells.
Another study administered GAL to see the effects of inhibiting G in dopaminergic neurons.
Abnormal levels of dopamine are thought to contribute to several neurological disorders including
PD. The study found G-Dopamine transporter interaction was affected by GAL ((Li, J., et
al.,2020). Our findings along with the studies mentioned further elucidates Ginvolvement in
MT assembly and organization and neurodegeneration.
Effect of GAL and TIDE on phosphorylation of TAU
In our study, when SHSY5Y cells were treated with GAL, expression of both TAU and
phosphorylated TAU were decreased. The result was not anticipated based on the fact that GAL
disrupted MTs in SHSY5Y cells. Because neurodegeneration is usually associated with
cytoskeletal disruption and Tau hyperphosphorylation, the result is intriguing, and suggests that
cytoskeletal disruption could also be associated with hypo-phosphorylation of Tau protein instead
of hyper-phosphorylation. In addition to GAL, TIDE was found to inhibit phosphorylation of
TAU. It might be the reason why TIDE was in clinical trial for Alzheimer disease.
Interestingly, however, It was found that TIDE increased Tau expression and
phosphorylation in RA-differentiated SHSY5Y cells as opposed to SHSY5Y cells (Fig.15).
Binding of RA triggers downstream activation of PI3K/AKT signaling (Kaplan DR, et al.,1993;
Edsio A, et al. 2003). PI3K is a major pathway that promotes neuronal survival (Wu,C.,et al.,
2019). Overexpression of GSK3in SHSY5Y was used to induce phosphorylation of TAU and
was successfully done in a previous study (Cortés-Gómez, M., et al., 2020). In comparison
previous results from our laboratory have shown that overexpression of Ginduced neuronal
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differentiation in PC12 cells in the absence of NGF. Further understanding of how these pathways
interact with each other may lead to a target for ND treatment.
Understanding G signaling pathway interaction with PI3K/AKT/GSK3
The relationship amongst G-MT and PI3K/AKT/GSK3 remains to be understood. Previous
results from our laboratory indicate both pAKT and pGSK3 expression is increased in the
presence of NGF differentiated PC12 cells. In the presence of GAL, NGF differentiated PC12
cells decreased expression of both pAKT and pGSK3. Overexpression of G in PC12 cells
increased expression of pGSK3, suggesting G directly interacts with GSK3promoting
phosphorylation. In our current study GAL significantly decreased expression of pGSK3 in
SHSY5Y and increased expression in RA-differentiated SHSY5Y. Similarly, TIDE also decreased
pGSK3 expression in SHSY5Y cells and increased expression in RA-differentiated SHSY5Y
cells. This event may explain why TIDE a GSK3 inhibitor increased expression of pGSK3 in
SHSY5Y cells.
Microscopic analysis of combined low and high concentrations of G and GSK3
inhibitors show that SHSY5Y cells seem to loss neuronal properties Colocalization of TUB/G
is seen throughout the cells. Synergistic use of inhibitors seems to have canceling effects on
neuronal differentiation. More studies need to be done to conclude. Furthermore, a study focusing
whether GSK3 and GSK3 are activated during dopaminergic neuronal loss, found that GSK3
is activated during dopaminergic cell death (Li, J., et al.,2020). As previously mentioned, another
study concluded that inhibition of G blocked G-DAT interactions (Garcia-Olivares, J., et
al.,2017). GAL decreased extracellular dopamine.
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Our study along with the studies mentioned above suggest that manipulation of G-MT
and PI3K/AKT/GSK3 pathway may lead to an understanding of how neurodegeneration occurs
and may lead to a drug model to treat ND.
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